BI8622, CAS [[1875036-74-0]]

Produktübersicht

• Artikelname: BI8622, CAS [[1875036-74-0]]
• Artikelnummer: MCE-HY-120929
• Hersteller Artikelnummer: HY-120929
• Alternativnummer: MCE-HY-120929-25MG,MCE-HY-120929-10MMX1ML,MCE-HY-120929-10MG,MCE-HY-120929-5MG,MCE-HY-120929-100MG,MCE-HY-120929-50MG
• Hersteller: MedchemExpress
• Kategorie: Biochemikalien

Produktbeschreibung

BI8622 is a specific inhibitor of the ubiquitin ligase HUWE1 with an IC50 of 3.1 µM. BI8622 can decrease the protein expression levels of c-myc and glycolytic markers as well as immune modulatory markers after HUWE1 inhibition in triple-negative breast cancer (TNBC) cell lines. BI8622 significantly protects against cisplatin (HY-17394)-induced acute kidney injury (AKI). BI8622 significantly reduces the growth of multiple myeloma (MM) cell lines and induces cell cycle arrest. BI8622 can prevent HUWE1-dependent TTBK2 ubiquitination. BI8622 can be studied in research for various diseases including medulloblastoma, acute kidney injury, breast cancer and MM[1][2][3][4][5].

Produkteigenschaften

• Molekulargewicht: 426.51
• Reinheit: 99.35
• CAS Nummer: [1875036-74-0]
• Formel: C25H26N6O
• Target-Kategorie: c-Myc,E1/E2/E3 Enzyme

Anwendungsbeschreibung

• Anwendungsbeschreibung: MCE Product type: Reference compound